Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Completed · Phase 3

Conditions studied: Breast Cancer

In brief

RATIONALE: The MAP.3 study was designed to test whether hormone therapy using exemestane may prevent breast cancer by blocking the production of estrogen. PURPOSE: The study protocol was amended in May 2011 and the current purpose of the study is to allow all study participants the opportunity to complete 5 years of exemestane.

Key facts

Study ID
NCT00083174
Run by
NCIC Clinical Trials Group
People needed
4560
Starts
2004-12-03
Expected to finish
2018-01-22
Last updated by the study team
2023-08-25

Who can join

Age: 35 and older. Sex: female. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.